Tumor Cell Nanovaccines Based on Genetically Engineered Antibody‐Anchored Membrane
Advanced Materials · 2023-03 · 35 (13)
DOI: 10.1002/adma.202208923 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 15.02.2023. Verfasst von Yuanke Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials for the Ministry of Education, College of Life Sciences and…. Hauptthemen laut MEDLINE: Antibodies, Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Nankai University Hundred Young Academic Leaders Program.
Abstract (Originalsprache)
Despite the promise in whole‐tumor cell vaccines, a key challenge is to overcome the lack of costimulatory signals. Here, agonistic‐antibody‐boosted tumor cell nanovaccines are reported by genetically engineered antibody‐anchored membrane (AAM) technology, capable of effectively activating costimulatory pathways. Specifically, the AAM can be stably constructed following genetic engineering of tumor cell membranes with anti‐CD40 single chain variable fragment (scFv), an agonistic antibody to induce costimulatory signals. The nanovaccines are versatilely designed and obtained based on the anti‐CD40 scFv‐anchored membrane and nanotechnology. Following vaccination, the anti‐CD40 scFv‐anchored membrane nanovaccine (Nano‐AAM/CD40) significantly facilitates dendritic cell maturation in CD40‐humanized transgenic mice and subsequent adaptive immune responses. Compared to membrane‐based nanovaccines alone, the enhanced antitumor efficacy in both “hot” and “cold” tumor models of the Nano‐AAM/CD40 demonstrates the importance of agonistic antibodies in development of tumor‐cell‐based vaccines. To expand the design of nanovaccines, further incorporation of cell lysates into the Nano‐AAM/CD40 to conceptually construct tumor cell‐like nanovaccines results in boosted immune responses and improved antitumor efficacy against malignant tumors inoculated into CD40‐humanized transgenic mice. Overall, this genetically engineered AAM technology provides a versatile design of nanovaccines by incorporation of tumor‐cell‐based components and agonistic antibodies of costimulatory immune checkpoints.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials for the Ministry of Education, College of Life Sciences and Frontiers Science Center for Cell Responses, Nankai University, Tianj…
- Joint Laboratory of Nanozymes, College of Life Sciences, Nankai University, Tianjin, 300071, P. R. China.
- Key Laboratory of Hebei Province for Molecular Biophysics, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin, 300401, P. R. China.
- School of Medicine, Nankai University, Tianjin, 300071, P. R. China.
ORCID-Profile: Xinglu Huang
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Nankai University Hundred Young Academic Leaders Program
- National Basic Research Program of China
Zitieren
APA
Li, Y., Zhang, H., Wang, R., Wang, Y., Li, R., Zhu, M., Zhang, X., Zhao, Z., Wan, Y., Zhuang, J., Zhang, H., & Huang, X. (2023). Tumor Cell Nanovaccines Based on Genetically Engineered Antibody‐Anchored Membrane. Advanced Materials, 35(13). https://doi.org/10.1002/adma.202208923
Vancouver
Li Y, Zhang H, Wang R, Wang Y, Li R, Zhu M, et al. Tumor Cell Nanovaccines Based on Genetically Engineered Antibody‐Anchored Membrane. Advanced Materials. 2023;35(13). doi:10.1002/adma.202208923
BibTeX
@article{Li2023,
author = {Li, Yuanke and Zhang, Haoqi and Wang, Ruikun and Wang, Yuan and Li, Ruonan and Zhu, Mingsheng and Zhang, Xiangyun and Zhao, Zhen and Wan, Yajuan and Zhuang, Jie and Zhang, Hongkai and Huang, Xinglu},
title = {Tumor Cell Nanovaccines Based on Genetically Engineered Antibody‐Anchored Membrane},
journal = {Advanced Materials},
year = {2023},
volume = {35},
number = {13},
doi = {10.1002/adma.202208923}
}
EUVIMED